Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
| ▸ | ARG1 | P05089 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28205391 | 1.00 | MAPT (0.56) | MAPTALDH1A1RECQLKDM4EGPR84 | |
| Hydrochloric Acid SCHEMBL21747182 | 0.99 | MAPT (0.55) | MAPTALDH1A1RECQLKDM4EGPR84 | |
| Hydrochloric Acid SCHEMBL18395377 | 0.99 | MAPT (0.55) | MAPTALDH1A1RECQLKDM4EGPR84 | |
| SCHEMBL31158206 | 0.87 | ALDH1A1 (0.55) | MAPTALDH1A1RECQLKDM4EGPR84 | |
| SCHEMBL21965973 | 0.87 | ALDH1A1 (0.55) | MAPTALDH1A1RECQLKDM4EGPR84 | |
| SCHEMBL1906546 | 0.87 | ALDH1A1 (0.55) | MAPTALDH1A1RECQLKDM4EGPR84 | |
| SCHEMBL1906547 | 0.87 | ALDH1A1 (0.55) | MAPTALDH1A1RECQLKDM4EGPR84 | |
| SCHEMBL2736359 | 0.87 | ALDH1A1 (0.55) | MAPTALDH1A1RECQLKDM4EGPR84 | |
| SCHEMBL29314027 | 0.86 | ALDH1A1 (0.55) | MAPTALDH1A1RECQLKDM4EGPR84 | |
| SCHEMBL23677906 | 0.86 | ALDH1A1 (0.54) | MAPTALDH1A1RECQLKDM4EGPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3613420-B1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | LUMOS PHARMA INC (US) | 2022-05-25 | — | — | EP | claimed |
| EP-3613420-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | Newlink Genetics Corporation (US) | 2020-02-26 | — | — | EP | claimed |
| US-10207990-B2 | Salts and prodrugs of 1-methyl-D-tryptophan | NEWLINK GENETICS CORPORATION (US) | 2019-02-19 | — | — | US | claimed |
| US-20180134658-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | LUMOS PHARMA, INC. | 2018-05-17 | — | — | US | claimed |
| US-9732035-B2 | Salts and prodrugs of 1-methyl-D-tryptophan | NEWLINK GENETICS CORPORATION (US) | 2017-08-15 | — | — | US | claimed |
| US-20170022157-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | LUMOS PHARMA, INC. | 2017-01-26 | — | — | US | claimed |
| US-11485705-B2 | Salts and prodrugs of 1-methyl-d-tryptophan | LUMOS PHARMA, INC. (US) | 2022-11-01 | — | — | US | disclosed |
| EP-3613420-B1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | LUMOS PHARMA INC (US) | 2022-05-25 | — | — | EP | disclosed |
| EP-3954369-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | Lumos Pharma, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3324958-B1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | LUMOS PHARMA INC (US) | 2021-07-28 | — | — | EP | disclosed |
| EP-3324958-B1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | LUMOS PHARMA INC (US) | 2021-07-28 | — | — | EP | disclosed |
| US-20200283385-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | LUMOS PHARMA, INC. | 2020-09-10 | — | — | US | disclosed |
| US-20200283385-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | LUMOS PHARMA, INC. | 2020-09-10 | — | — | US | disclosed |
| US-9732035-B2 | Salts and prodrugs of 1-methyl-D-tryptophan | NEWLINK GENETICS CORPORATION (US) | 2017-08-15 | — | — | US | disclosed |
| US-9732035-B2 | Salts and prodrugs of 1-methyl-D-tryptophan | NEWLINK GENETICS CORPORATION (US) | 2017-08-15 | — | — | US | disclosed |
| US-9732035-B2 | Salts and prodrugs of 1-methyl-D-tryptophan | NEWLINK GENETICS CORPORATION (US) | 2017-08-15 | — | — | US | disclosed |
| WO-2017019175-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | NEWLINK GENETICS CORPORATION (US) | 2017-02-02 | — | — | WO | disclosed |
| US-20170022157-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | LUMOS PHARMA, INC. | 2017-01-26 | — | — | US | disclosed |
| US-20170022157-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | LUMOS PHARMA, INC. | 2017-01-26 | — | — | US | disclosed |
| US-20170022157-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | LUMOS PHARMA, INC. | 2017-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10207990-B2 | Salts and prodrugs of 1-methyl-D-tryptophan | IDO1, IDO2, INMT | MAPT 2135/4885ALDH1A1 634/4885RECQL 2301/4885 |
| US-20200283385-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | IDO1, IDO2, INMT | MAPT 2135/4885ALDH1A1 634/4885RECQL 2301/4885 |
| US-11485705-B2 | Salts and prodrugs of 1-methyl-d-tryptophan | IDO1, IDO2, INMT | MAPT 2135/4885ALDH1A1 634/4885RECQL 2301/4885 |
| US-20170022157-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | IDO1, IDO2, INMT | MAPT 2135/4885ALDH1A1 634/4885RECQL 2301/4885 |
| US-20180134658-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | IDO1, IDO2, INMT | MAPT 2135/4885ALDH1A1 634/4885RECQL 2301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.